BioHarvest Sciences EBITDA Margin 2020-2024 | BHST
Current and historical EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) margin for BioHarvest Sciences (BHST) over the last 10 years. The current EBITDA margin for BioHarvest Sciences as of June 30, 2024 is .
| BioHarvest Sciences EBITDA Margin Historical Data |
| Date |
TTM Revenue |
TTM EBITDA |
EBITDA Margin |
| 2024-06-30 |
$0.02B |
$-0.01B |
-31.58% |
| 2024-03-31 |
$0.02B |
$-0.01B |
-50.00% |
| 2023-12-31 |
$0.01B |
$-0.01B |
-69.23% |
| 2023-09-30 |
$0.01B |
$-0.01B |
-90.00% |
| 2023-06-30 |
$0.01B |
$-0.01B |
-111.11% |
| 2023-03-31 |
$0.01B |
$-0.01B |
-128.57% |
| 2022-12-31 |
$0.01B |
$-0.01B |
-150.00% |
| 2022-09-30 |
$0.01B |
$-0.01B |
-160.00% |
| 2022-06-30 |
$0.00B |
$-0.01B |
-200.00% |
| 2022-03-31 |
$0.00B |
$-0.01B |
-266.67% |
| 2021-12-31 |
$0.00B |
$-0.01B |
-400.00% |
| 2021-09-30 |
$0.00B |
$-0.01B |
-900.00% |
| 2021-06-30 |
$0.00B |
$-0.01B |
inf% |
| 2021-03-31 |
$0.00B |
$-0.01B |
inf% |
| 2020-12-31 |
$0.00B |
$-0.01B |
inf% |
| 2020-06-30 |
$0.00B |
$-0.00B |
inf% |
| 2020-03-31 |
$0.00B |
$-0.00B |
inf% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$0.098B |
$0.013B |
|
BioHarvest Sciences Inc. is a biotech firm. It focused on leveraging its botanical synthesis technology to develop science-based and clinically proven therapeutic solutions, within business verticals nutraceutical health and wellness products such as dietary supplements and development of plant cell-based Active Pharmaceutical Ingredients which focus on specific medical indications. BioHarvest Sciences Inc. is based in Vancouver, Canada.
|
